

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1.-21. (Cancelled)

22. (Currently Amended) A method for screening for a molecule that modulates ~~the function, gamma-secretase activity, composition, or formation of the complex of claim 1~~ comprising, which method comprises the steps of:

- (a) exposing ~~said complex~~ a protein complex comprising (i) Sambiasin-1 (SEQ ID NO: 1), (ii) Presenilin-1 (SEQ ID NO: 2), and (iii) Nicastrin (SEQ ID NO: 3), or a cell or organism containing ~~said the~~ the complex to one or more candidate molecules; and
- (b) determining the ~~amount of, gamma-secretase activity of, protein components of, and/or intracellular localization of, said the complex and/or the transcription level of a gene dependent on the complex and/or the abundance and/or activity of a protein or protein complex dependent on the function of the complex and/or product of a gene dependent on the complex in the presence of the one or more candidate molecules, wherein a change in said amount, an increase or decrease in gamma-secretase activity, protein components or intracellular localization relative to said the amount, gamma-secretase activity, protein components and/or intracellular localization and/or a change in the transcription level of a gene dependent on the complex and/or the abundance and/or activity of a protein or protein complex dependent on the function of the complex and/or product of a gene dependent on~~ of the complex in the absence of said the one or more candidate molecules indicates that the molecule modulates function, one or more candidate molecules modulate gamma-secretase activity or composition of said the complex.

23.-24. (Cancelled)

25. (Currently Amended) The method of claim 24 ~~22~~, wherein ~~said the~~ the determining step comprises isolating from the cell or organism ~~said the~~ the complex to produce ~~said an~~ an isolated complex and contacting ~~said the~~ the isolated complex in the presence or absence of a candidate molecule with a physiological substrate of the complex and ~~determine~~ determining whether ~~said the~~ the substrate is processed.

26. (Currently Amended) The method of claim 22, wherein the amount of the individual protein components of said the complex are determined.

27. (Cancelled)

28. (Currently Amended) The method of claim 22, wherein said ~~method is a method of screening for~~ the candidate molecule is a drug for treatment or prevention of ~~a disease or disorder, wherein the disease or disorder is selected from the group consisting of neurodegenerative diseases and developmental disorders caused by defects in the Notch pathway~~ Alzheimer's disease.

29.-49. (Cancelled)